The earnings headline was better than the standing estimate, but the operating picture was not. Adjusted EPS was $0.39 versus a published consensus near $0.29, while sales fell 6% year over year to $999.7 million; with 2026 guidance withdrawn after the pending acquisition announcement, there is no company outlook against which to measure the quarter.
| Metric | 2Q 2026 | 2Q 2025 / reference | Read |
|---|---|---|---|
| Trade sales | $999.7 million | $1,058.0 million | Down 6% (Income Statement) |
| Organic sales | Down 1% | — | Better than reported sales because divestitures reduced sales 5% (Second quarter EBIT) |
| Volume | Down 4% | — | Broad demand weakness (Second quarter EBIT) |
| Reported EPS | $0.33 | $0.38 | Down 13% (Income Statement) |
| Adjusted EPS | $0.39 | $0.30 | Up $0.09 (Non-GAAP reconciliation) |
| Reported EBIT | $80.1 million | $90.4 million | Down 11% (Income Statement) |
| Adjusted EBIT | $89.0 million | $75.6 million | Up 18% (Non-GAAP reconciliation) |
| Operating cash flow | $45.8 million | $84.0 million | Down 45% (Cash Flow statement) |
| Net debt / adjusted EBITDA | 2.57x | 3.51x | Improved mainly after prior divestiture proceeds (Net Debt to Adjusted EBITDA) |
The adjusted EPS beat is low quality. Adjusted EBIT benefited from metal-margin expansion, restructuring benefits, tariff refunds, and other favorable items that management says mostly will not repeat; reported EBIT actually declined, and the reported margin fell to 8.0% from 8.5% (EBIT margin; Non-GAAP reconciliation).
Underlying demand remains the main problem. Company-wide volume fell 4%, U.S. mattress units declined by low double digits, and Bedding volume dropped 7% despite trade sales declining only 1% because pricing and currency added 6% (Segment results — Bedding Products). Specialized Products was weaker still: trade sales fell 19% after the Aerospace divestiture, while adjusted EBIT fell 40% (Segment results — Specialized Products).
Cash conversion was materially worse, limiting the value of the earnings beat. Operating cash flow fell to $45.8 million as working capital absorbed cash and earnings were lower; capital expenditures also increased to $20.5 million from $8.5 million (Cash Flow statement). The balance sheet is manageable at 2.57x net debt to trailing adjusted EBITDA, but the quarter did not show stronger cash generation (Net Debt to Adjusted EBITDA).
The merger is now the dominant near-term framing, not a renewed operating recovery. Leggett reiterated that the Somnigroup transaction is progressing, with shareholder approval scheduled for August 20, 2026, but remaining regulatory and closing conditions still apply; guidance remains withdrawn and there will be no conference call (2026 Guidance and Conference Call). Net: the adjusted profit surprise is favorable versus the limited published benchmark, but weak volumes, nonrecurring earnings support, and deteriorating cash flow make the overall filing mixed rather than a clean operational beat.
Read the original 8-K on SEC EDGAR ↗